Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab

Journal of Immunotherapy

Volumn 38, Issue 5, 2015, Pages 212-215

  Uslu, Ugur ^a   Agaimy, Abbas ^a   Hundorfean, Gheorghe ^a   Harrer, Thomas ^a   Schuler, Gerold ^a   Heinzerling, Lucie ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Autoimmune colitis; CMV hepatitis; Immune related adverse effects; Ipilimumab; Melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GANCICLOVIR; IMMUNOGLOBULIN G; INFLIXIMAB; IPILIMUMAB; PREDNISONE; VIRUS DNA; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CANCER IMMUNOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CASE REPORT; COLITIS; COLON PERFORATION; COLONOSCOPY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOGRAPHY; FECES CULTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; METASTATIC MELANOMA; MIDDLE AGED; NECK DISSECTION; NEUTROPHIL CHEMOTAXIS; PARENTERAL NUTRITION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM HEMORRHAGE; SIDE EFFECT; SOFT TISSUE METASTASIS; THYROID METASTASIS; TOXIC HEPATITIS; VIRUS HEPATITIS; VIRUS REPLICATION; AUTOIMMUNE DISEASES; COMPLICATION; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS; MELANOMA; METASTASIS; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; COLITIS; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84929671026     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000081     Document Type: Article

References (10)

1. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.
2. Kralickova P, Mala E, Vokurkova D, et al. Cytomegalovirus disease in patients with common variable immunodeficiency: three case reports. Int Arch Allergy Immunol. 2014;163:69-74.
3. Harrison GJ. Cytomegalovirus. In: Cherry JD, Harrison GJ, Kaplan SL, et al, eds. Feigin and Cherrys Textbook of Pediatric Infectious Disease, 7th ed. Philadelphia: Elsevier Saunders; 2014:1969.
4. Jaber S, Chanques G, Borry J, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest. 2005;127:233-241.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
6. du Rusquec P, Saint-Jean M, Brocard A, et al. Ipilimumabinduced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother. 2014;37:348-350.
7. Gaudy-Marqueste C, Monestier S, Franques J, et al. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013; 36:77-78.
8. Weber JS, Kähler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
9. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol. 2012;6:53-66.
10. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013;31:1071-1077.